Selinexor for Heavily Pretreated RRRMM

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.

Michael Barish, PhD

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Ariana Pelosci

How Supportive Care Methods Can Improve Oncology Outcomes

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.

Experts discussed supportive care and why it should be integrated into standard oncology care.

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD

November 10th 2025

Omitting Lymphadenectomy Reduces AEs, Does Not Lower DFS in Cervical Cancer

Experts discussed supportive care and why it should be integrated into standard oncology care.

The 3-year DFS rate was 96.9% in patients who received sentinel-lymph node biopsy alone vs 94.6% in those who received lymphadenectomy.

FDA Grants Fast Track Designation to Novel Imaging Agent in Clear Cell RCC

The 3-year DFS rate was 96.9% in patients who received sentinel-lymph node biopsy alone vs 94.6% in those who received lymphadenectomy.

A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

Real-World Niraparib Efficacy Similar to Phase 3 Data in Ovarian Cancer

A first-in-human phase 1/2 trial is evaluating the theranostic pair of ITM-91 and ITM-94 in patients with solid tumors.

Related Content

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

The median PFS for patients with ovarian cancer who received niraparib maintenance in the real-world setting was 25.7 months.

Michael Barish, PhD

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

Ariana Pelosci

How Supportive Care Methods Can Improve Oncology Outcomes

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD

November 10th 2025

Omitting Lymphadenectomy Reduces AEs, Does Not Lower DFS in Cervical Cancer

Experts discussed supportive care and why it should be integrated into standard oncology care.

FDA Grants Fast Track Designation to Novel Imaging Agent in Clear Cell RCC

The 3-year DFS rate was 96.9% in patients who received sentinel-lymph node biopsy alone vs 94.6% in those who received lymphadenectomy.